Does PACIRA BIOSCIENCES, INC. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores PACIRA BIOSCIENCES, INC. (PCRX) 40.2 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 95, returns on capital 4, balance-sheet safety 28, capital discipline 25.

Is PCRX stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $33.86 per share versus a recent price of $25.61 — 24% below value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has PCRX's Moat Score changed over time?

The record logs 3 readings since Jul 17, 2026; the latest reads 40.2 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

PACIRA BIOSCIENCES, INC.

PCRX · Healthcare · $1.1B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power95

Median gross margin 73.3% over 10y, very stable.

Returns on capital4

Median ROIC 3.7%, above the 9% hurdle in 10% of years.

Balance-sheet safety28

Net debt/EBITDA 1.9x, interest coverage 1x.

Capital discipline25

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

24% below value

Owner earnings (normalized): $77.3M
Est. intrinsic value / share: $33.86
Recent price: $25.61
Discount to value: 24% below value

Conservative model: 9% discount rate, 4% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

18 years of fundamentals

The business, in plain English

PACIRA BIOSCIENCES, INC. booked $726.4M of revenue in FY2025 in the Healthcare sector and kept 79.4% of it as gross profit — a high-margin business by that measure. After every other cost, 1.0% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $15.0M (FY2009) to $726.4M (FY2025) — about 27.4% a year compounded over 16 years.

It earned 1.4% on invested capital in FY2025, with a median of 1.4% across 15 filed years. The Returns on Capital filter above scores it 4/100.

The balance sheet carried $372.2M of total debt in FY2025 against $82.7M of owner earnings — roughly 4.5 years of owner earnings to retire it all. Balance-Sheet Safety scores it 28/100.

The share count rose 7062.8% between FY2010 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 25/100.

Put together: Pricing Power is the strongest of the four filters (95/100) and Returns on Capital the weakest (4/100), which is how PCRX lands at 40/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$726.4M FY2025

Gross marginRevenue kept after cost of goods79.4% FY2025

Return on invested capitalOperating profit on the capital employed1.4% FY2025

Owner earningsCash an owner could take out$82.7M FY2025

Gaps in a line mean that item isn’t in PCRX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale40.2 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — PCRX has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#245 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#243NPCE NEUROPACE, INC.40.3 out of 100, Shallow moatShallow moat
#244TMCI Treace Medical Concepts, Inc.40.3 out of 100, Shallow moatShallow moat
#246AGEN AGENUS INC40.0 out of 100, Shallow moatShallow moat
#247PGEN PRECIGEN, INC.40.0 out of 100, Shallow moatShallow moat

Compare PCRX with its nearest peers →All Healthcare companies on the Index →

Common questions about PCRX

Does PACIRA BIOSCIENCES, INC. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores PACIRA BIOSCIENCES, INC. (PCRX) 40.2 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 95, returns on capital 4, balance-sheet safety 28, capital discipline 25.
Is PCRX stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $33.86 per share versus a recent price of $25.61 — 24% below value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has PCRX's Moat Score changed over time?: The record logs 3 readings since Jul 17, 2026; the latest reads 40.2 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows PCRX’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/PCRX"
  width="340" height="150" style="border:0"
  title="PCRX Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell PCRX. See the disclaimer.